These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 35580987)
1. DUSP4 protects BRAF- and NRAS-mutant melanoma from oncogene overdose through modulation of MITF. Gutierrez-Prat N; Zuberer HL; Mangano L; Karimaddini Z; Wolf L; Tyanova S; Wellinger LC; Marbach D; Griesser V; Pettazzoni P; Bischoff JR; Rohle D; Palladino C; Vivanco I Life Sci Alliance; 2022 Sep; 5(9):. PubMed ID: 35580987 [TBL] [Abstract][Full Text] [Related]
2. Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells. Pathria G; Garg B; Borgdorff V; Garg K; Wagner C; Superti-Furga G; Wagner SN Cell Death Dis; 2016 Mar; 7(3):e2135. PubMed ID: 26962685 [TBL] [Abstract][Full Text] [Related]
3. P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition. Najem A; Krayem M; Salès F; Hussein N; Badran B; Robert C; Awada A; Journe F; Ghanem GE Eur J Cancer; 2017 Sep; 83():154-165. PubMed ID: 28738256 [TBL] [Abstract][Full Text] [Related]
4. Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy. Smith MP; Brunton H; Rowling EJ; Ferguson J; Arozarena I; Miskolczi Z; Lee JL; Girotti MR; Marais R; Levesque MP; Dummer R; Frederick DT; Flaherty KT; Cooper ZA; Wargo JA; Wellbrock C Cancer Cell; 2016 Mar; 29(3):270-284. PubMed ID: 26977879 [TBL] [Abstract][Full Text] [Related]
5. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Konieczkowski DJ; Johannessen CM; Abudayyeh O; Kim JW; Cooper ZA; Piris A; Frederick DT; Barzily-Rokni M; Straussman R; Haq R; Fisher DE; Mesirov JP; Hahn WC; Flaherty KT; Wargo JA; Tamayo P; Garraway LA Cancer Discov; 2014 Jul; 4(7):816-27. PubMed ID: 24771846 [TBL] [Abstract][Full Text] [Related]
6. Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma. Fedorenko IV; Fang B; Munko AC; Gibney GT; Koomen JM; Smalley KS Proteomics; 2015 Jan; 15(2-3):327-39. PubMed ID: 25339196 [TBL] [Abstract][Full Text] [Related]
7. Paralog knockout profiling identifies DUSP4 and DUSP6 as a digenic dependence in MAPK pathway-driven cancers. Ito T; Young MJ; Li R; Jain S; Wernitznig A; Krill-Burger JM; Lemke CT; Monducci D; Rodriguez DJ; Chang L; Dutta S; Pal D; Paolella BR; Rothberg MV; Root DE; Johannessen CM; Parida L; Getz G; Vazquez F; Doench JG; Zamanighomi M; Sellers WR Nat Genet; 2021 Dec; 53(12):1664-1672. PubMed ID: 34857952 [TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma. Wong DJ; Robert L; Atefi MS; Lassen A; Avarappatt G; Cerniglia M; Avramis E; Tsoi J; Foulad D; Graeber TG; Comin-Anduix B; Samatar A; Lo RS; Ribas A Mol Cancer; 2014 Aug; 13():194. PubMed ID: 25142146 [TBL] [Abstract][Full Text] [Related]
9. Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma. Gupta A; Towers C; Willenbrock F; Brant R; Hodgson DR; Sharpe A; Smith P; Cutts A; Schuh A; Asher R; Myers K; Love S; Collins L; Wise A; Middleton MR; Macaulay VM Br J Cancer; 2020 Feb; 122(4):506-516. PubMed ID: 31839677 [TBL] [Abstract][Full Text] [Related]
10. Loss of BOP1 confers resistance to BRAF kinase inhibitors in melanoma by activating MAP kinase pathway. Gupta R; Bugide S; Wang B; Green MR; Johnson DB; Wajapeyee N Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4583-4591. PubMed ID: 30782837 [TBL] [Abstract][Full Text] [Related]
11. Regulation of CEACAM1 Protein Expression by the Transcription Factor ETS-1 in BRAF-Mutant Human Metastatic Melanoma Cells. Kfir-Elirachman K; Ortenberg R; Vizel B; Besser MJ; Barshack I; Schachter J; Nemlich Y; Markel G Neoplasia; 2018 Apr; 20(4):401-409. PubMed ID: 29558679 [TBL] [Abstract][Full Text] [Related]